% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Barba:274050,
      author       = {Barba, Lorenzo and Vollmuth, Christoph and Halbgebauer,
                      Steffen and Ungethüm, Kathrin and Hametner, Christian and
                      Essig, Fabian and Kollikowski, Alexander M and Pham, Mirko
                      and Schuhmann, Michael K and Heuschmann, Peter U and Oeckl,
                      Patrick and Steinacker, Petra and Romoli, Michele and
                      D'Anna, Lucio and Abu-Rumeileh, Samir and Haeusler, Karl
                      Georg and Stoll, Guido and Neugebauer, Hermann and Otto,
                      Markus},
      title        = {{P}rognostic serum biomarkers of synaptic, neuronal and
                      glial injury in patients with acute ischemic stroke of the
                      anterior circulation.},
      journal      = {European journal of neurology},
      volume       = {32},
      number       = {1},
      issn         = {1351-5101},
      address      = {Oxford [u.a.]},
      publisher    = {Wiley-Blackwell},
      reportid     = {DZNE-2025-00031},
      pages        = {e16581},
      year         = {2025},
      abstract     = {We aimed to investigate the prognostic role of β-synuclein
                      in comparison to that of neurofilament light chain (NfL) and
                      glial fibrillary acidic protein (GFAP) for predicting
                      functional outcome after acute ischemic stroke (AIS).We
                      measured serum concentrations of β-synuclein, NfL and GFAP
                      24 h after hospital admission in 213 consecutive patients
                      with moderate-to-severe AIS. We investigated the association
                      between serum biomarkers and radiological/clinical
                      characteristics, 3-months mortality and functional outcome
                      on the modified Rankin Scale (mRS).In 213 patients with AIS
                      [mean age: 76.1 (±12.5) years, $53.1\%$ males, median NIHSS
                      score on admission: 13 (IQR: 9-17)], higher levels of
                      β-synuclein, NfL and GFAP were associated with higher NIHSS
                      scores and with lower Alberta Stroke Program CT Score
                      (ASPECTS) points on admission. Serum β-synuclein levels was
                      significantly correlated with NfL (rho = 0.715, p < 0.001)
                      and GFAP concentrations (rho = 0.684, p < 0.001). The
                      inclusion of serum β-synuclein significantly improved the
                      accuracy of prediction models without biomarkers for overall
                      mortality (AUC: 0.836 vs. 0.752, p < 0.001) and mRS 3-6 vs.
                      0-2 (AUC: 0.812 vs. 0.624, p < 0.001). Combination models
                      with NfL and/or GFAP showed a similar accuracy.Serum
                      β-synuclein may be used to assess synaptic
                      damage/dysfunction and to predict 3-months clinical outcomes
                      in patients with AIS.},
      keywords     = {Humans / Male / Female / Aged / Biomarkers: blood /
                      Ischemic Stroke: blood / Ischemic Stroke: mortality /
                      Prognosis / Aged, 80 and over / Glial Fibrillary Acidic
                      Protein: blood / Neurofilament Proteins: blood / Middle Aged
                      / Neuroglia / Neurons: pathology / Synapses / GFAP (Other) /
                      NfL (Other) / beta‐synuclein (Other) / biomarkers (Other)
                      / stroke (Other) / Biomarkers (NLM Chemicals) / Glial
                      Fibrillary Acidic Protein (NLM Chemicals) / neurofilament
                      protein L (NLM Chemicals) / Neurofilament Proteins (NLM
                      Chemicals) / GFAP protein, human (NLM Chemicals)},
      cin          = {Clinical Study Center (Ulm) / AG Öckl},
      ddc          = {610},
      cid          = {I:(DE-2719)5000077 / I:(DE-2719)5000073},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39714176},
      pmc          = {pmc:PMC11664725},
      doi          = {10.1111/ene.16581},
      url          = {https://pub.dzne.de/record/274050},
}